BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Aguilar JC, Aguiar JA, Akbar SMF. Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. Vaccines (Basel) 2022;10. [PMID: 36560498 DOI: 10.3390/vaccines10122087] [Reference Citation Analysis]
2 Zheng J, Wang Z, Feng B. Hepatitis B functional cure and immune response. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1075916] [Reference Citation Analysis]
3 Akbar SMF, Mahtab MA, Khan S, Yoshida O, Hiasa Y. Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection. Vaccines (Basel) 2022;10. [PMID: 36298512 DOI: 10.3390/vaccines10101644] [Reference Citation Analysis]
4 Mu Y, Ren XH, Han D, Guan YY, Liu PL, Cheng SX, Liu H. Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity. Pharmaceutics 2022;14:1439. [PMID: 35890334 DOI: 10.3390/pharmaceutics14071439] [Reference Citation Analysis]
5 Hao Y, Gu Z, Yu Z, Schomann T, Sayedipour S, Aguilar JC, Ten Dijke P, Cruz LJ. Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. Cancers (Basel) 2022;14:2724. [PMID: 35681703 DOI: 10.3390/cancers14112724] [Reference Citation Analysis]
6 Tai J, Han M, Lee D, Park I, Lee SH, Kim TH. Different Methods and Formulations of Drugs and Vaccines for Nasal Administration. Pharmaceutics 2022;14:1073. [DOI: 10.3390/pharmaceutics14051073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
8 Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Akbar SMF, Yoshida O, Hiasa Y. Immune therapies against chronic hepatitis B. J Gastroenterol 2022;57:517-28. [PMID: 35708793 DOI: 10.1007/s00535-022-01890-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial. Vaccines (Basel) 2021;10:45. [PMID: 35062707 DOI: 10.3390/vaccines10010045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]